GDXJ vs IBB
VanEck Junior Gold Miners ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.52% for GDXJ.
- • GDXJ pays a higher dividend yield (2.77%).
Side-by-side metrics
| Metric | GDXJ | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.52% | 0.44% |
Dividend yield Trailing 12-month yield. | 2.77% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $7.08B | $11.50B |
YTD return | -0.63% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.17 | 0.60 |
P/E ratio | 12.72 | 25.48 |
Last price | $105.88 | $217.75 |
Inception | — | — |
Issuer | VanEck | iShares |
GDXJ top holdings
| AGI.TO | Alamos Gold Inc Class A | 6.52% |
| EQX.TO | Equinox Gold Corp Ordinary Shares Class A | 6.11% |
| CDE | Coeur Mining Inc | 5.89% |
| EDV.L | Endeavour Mining PLC | 5.83% |
| IMG.TO | Iamgold Corp | 5.07% |
| PE&OLES.MX | Industrias Penoles SAB de CV | 2.62% |
| HL | Hecla Mining Co | 2.26% |
| AG.TO | First Majestic Silver Corp | 2.23% |
| LUG.TO | Lundin Gold Inc | 2.07% |
| BTO.TO | B2Gold Corp | 1.85% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About GDXJ
GDXJ (VanEck Junior Gold Miners ETF) is Small and mid-cap gold and silver mining companies. Managed by VanEck, the fund carries $7.1B in assets under management, an expense ratio of 0.52%, a dividend yield of 2.77%. Its largest holding is Alamos Gold Inc Class A (AGI.TO), which represents 6.5% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.